Abstract
Background: Metabolic syndromes such as insulin resistance, type 2 diabetes and obesity share common pathogenic pathways with some age-related neurodegenerative disorders. Impaired insulin signaling, inflammation, mitochondrial dysfunction and ER stress can be both causatives and consequences in both groups of the diseases. Patients with chronic metabolic disorders therefore have potential risks to develop neurological diseases in late-age phase and vice versa those who with neurodegenerative diseases also have impairments in metabolic signaling. Method: In this review, we summarize about the interrelation between pathogenic pathways, common drug targets as well as known and developing therapeutics for these “modern” diseases. Results: There are conventional medicines for insulin resistance associated metabolic disorders such as insulin analogues, insulin sensitizers and ER stress releasers which have been suggested in the treatments of some neurodegenerative diseases. Some used or tested therapeutics such as bromocriptine, memantine and -2A adrenergic antagonists for Parkinson’s and Alzheimer’s diseases, vice versa, were promisingly shown as alternative or complementary drugs for metabolic syndromes. Conclusion: Therefore, it is important and possible to consider contemporary control and intervention for both diseases.
Keywords: Therapeutics, metabolic disorders, neurodegenerative diseases, common pathways.
Current Pharmaceutical Design
Title:Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Volume: 22 Issue: 23
Author(s): Xuan Thi-Anh Nguyen and Ly Le
Affiliation:
Keywords: Therapeutics, metabolic disorders, neurodegenerative diseases, common pathways.
Abstract: Background: Metabolic syndromes such as insulin resistance, type 2 diabetes and obesity share common pathogenic pathways with some age-related neurodegenerative disorders. Impaired insulin signaling, inflammation, mitochondrial dysfunction and ER stress can be both causatives and consequences in both groups of the diseases. Patients with chronic metabolic disorders therefore have potential risks to develop neurological diseases in late-age phase and vice versa those who with neurodegenerative diseases also have impairments in metabolic signaling. Method: In this review, we summarize about the interrelation between pathogenic pathways, common drug targets as well as known and developing therapeutics for these “modern” diseases. Results: There are conventional medicines for insulin resistance associated metabolic disorders such as insulin analogues, insulin sensitizers and ER stress releasers which have been suggested in the treatments of some neurodegenerative diseases. Some used or tested therapeutics such as bromocriptine, memantine and -2A adrenergic antagonists for Parkinson’s and Alzheimer’s diseases, vice versa, were promisingly shown as alternative or complementary drugs for metabolic syndromes. Conclusion: Therefore, it is important and possible to consider contemporary control and intervention for both diseases.
Export Options
About this article
Cite this article as:
Thi-Anh Nguyen Xuan and Le Ly, Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders, Current Pharmaceutical Design 2016; 22 (23) . https://dx.doi.org/10.2174/1381612822666160420141325
DOI https://dx.doi.org/10.2174/1381612822666160420141325 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cells in Amyotrophic Lateral Sclerosis: Motor Neuron Protection or Replacement?
CNS & Neurological Disorders - Drug Targets Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Coenzyme Q10 and Neurological Diseases: An Update
Letters in Drug Design & Discovery p75NTR as a Therapeutic Target for Neuropsychiatric Diseases
Current Molecular Pharmacology Potential Beneficial Effects of Marine Peptide on Human Neuron Health
Current Protein & Peptide Science Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
CNS & Neurological Disorders - Drug Targets Development and Applications of Non-HIV-Based Lentiviral Vectors in Neurological Disorders
Current Gene Therapy Positron Emission Tomography and Brain Monoamine Neurotransmission - Entries for Study of Drug Interactions
Current Pharmaceutical Design Neuropharmacology of Cannabinoid System: From Basic Science to Clinical Applications
Current Neuropharmacology Meet Our Editorial Board Member
Current Alzheimer Research Are the Extracelluar Pathways a Conduit for the Delivery of Therapeutics to the Brain?
Current Pharmaceutical Design Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?
Current Neuropharmacology Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Editorial (Thematic Issue: Neurobiological and Neurocognitive Basis of the Effects of Cannabinoids in Animals and Man: Therapeutic Potential of Cannabinoids in Psychiatry)
Current Pharmaceutical Design Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry Imidazole: An Essential Edifice for the Identification of New Lead Compounds and Drug Development
Mini-Reviews in Medicinal Chemistry Protective Ability of Perovskia abrotanoides Karel Root Extract on the Aggregation of Protein In Vitro
The Natural Products Journal